These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 38426090)

  • 1. Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.
    Wang X; Yuan Z; Li Z; He X; Zhang Y; Wang X; Su J; Wu X; Li M; Du F; Chen Y; Deng S; Zhao Y; Shen J; Yi T; Xiao Z
    Front Immunol; 2024; 15():1354313. PubMed ID: 38426090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
    Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
    Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity and mechanism of oligoclonal hepatocellular carcinoma tumor-infiltrating lymphocytes
    Wang WC; Zhang ZQ; Li PP; Ma JY; Chen L; Qian HH; Shi LH; Yin ZF; Sun B; Zhang XF
    Cancer Biol Ther; 2019; 20(9):1187-1194. PubMed ID: 31018748
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.
    Granhøj JS; Witness Præst Jensen A; Presti M; Met Ö; Svane IM; Donia M
    Expert Opin Biol Ther; 2022 May; 22(5):627-641. PubMed ID: 35414331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
    Kang HJ; Oh JH; Chun SM; Kim D; Ryu YM; Hwang HS; Kim SY; An J; Cho EJ; Lee H; Shim JH; Sung CO; Yu E
    J Hepatol; 2019 Jul; 71(1):91-103. PubMed ID: 30930222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management.
    Shirabe K; Motomura T; Muto J; Toshima T; Matono R; Mano Y; Takeishi K; Ijichi H; Harada N; Uchiyama H; Yoshizumi T; Taketomi A; Maehara Y
    Int J Clin Oncol; 2010 Dec; 15(6):552-8. PubMed ID: 20963618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
    Jiang SS; Tang Y; Zhang YJ; Weng DS; Zhou ZG; Pan K; Pan QZ; Wang QJ; Liu Q; He J; Zhao JJ; Li J; Chen MS; Chang AE; Li Q; Xia JC
    Oncotarget; 2015 Dec; 6(38):41339-49. PubMed ID: 26515587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas.
    Hsiao YW; Chiu LT; Chen CH; Shih WL; Lu TP
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31434354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of adoptive cell therapy in hepatocellular carcinoma.
    Wu D; Li Y
    Immunology; 2023 Dec; 170(4):453-469. PubMed ID: 37435926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
    Fix SM; Forget MA; Sakellariou-Thompson D; Wang Y; Griffiths TM; Lee M; Haymaker CL; Dominguez AL; Basar R; Reyes C; Kumar S; Meyer LA; Hwu P; Bernatchez C; Jazaeri AA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35882447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma.
    Chan AW; Zhang Z; Chong CC; Tin EK; Chow C; Wong N
    J Pathol; 2019 Oct; 249(2):166-172. PubMed ID: 31168847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
    Kazemi MH; Sadri M; Najafi A; Rahimi A; Baghernejadan Z; Khorramdelazad H; Falak R
    Front Immunol; 2022; 13():1018962. PubMed ID: 36389779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
    Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
    Kumar A; Watkins R; Vilgelm AE
    Front Immunol; 2021; 12():690499. PubMed ID: 34140957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The density of tumor-infiltrating lymphocytes and prognosis in resectable hepatocellular carcinoma: a two-phase study.
    Gao F; Xie K; Xiang Q; Qin Y; Chen P; Wan H; Deng Y; Huang J; Wu H
    Aging (Albany NY); 2021 Mar; 13(7):9665-9678. PubMed ID: 33744864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
    Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancements in tumor-infiltrating lymphocytes: Historical insights, contemporary milestones, and future directions in oncology therapy.
    Aizaz M; Khan AS; Khan M; Musazade E; Yang G
    Crit Rev Oncol Hematol; 2024 Oct; 202():104471. PubMed ID: 39117163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?
    Li B
    Front Immunol; 2022; 13():973881. PubMed ID: 36341370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.